SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001078782-20-000386
Filing Date
2020-05-29
Accepted
2020-05-28 17:33:45
Documents
4
Period of Report
2020-05-14
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K/A AMENDED CURRENT REPORT f8ka051420_8kz.htm 8-K/A 17290
2 EXHIBIT 99.1 THE AUDITED FINANCIAL STATEMENTS OF SAPPHIRE AS OF AND FOR THE YEAR f8ka051420_ex99z1.htm EX-99.1 146554
3 EXHIBIT 99.2 THE UNAUDITED PRO FORMA COMBINED CONSOLIDATED BALANCE SHEET AS OF A f8ka051420_ex99z2.htm EX-99.2 140209
4 IMAGE f8ka0514208kz1.jpg GRAPHIC 28546
  Complete submission text file 0001078782-20-000386.txt   344085
Mailing Address 45 ROCKEFELLER PLAZA 20TH FLOOR, STE 83 NEW YORK NY 10022
Business Address 45 ROCKEFELLER PLAZA 20TH FLOOR, STE 83 NEW YORK NY 10022 (212) 751-0001
AXIM BIOTECHNOLOGIES, INC. (Filer) CIK: 0001514946 (see all company filings)

IRS No.: 274092986 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 000-54296 | Film No.: 20922508
SIC: 2834 Pharmaceutical Preparations